Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Meta-Analysis
. 2023 Oct;192(5):2129-2141.
doi: 10.1007/s11845-023-03276-y. Epub 2023 Jan 31.

Copeptin and the prognosis of patients with coronary artery disease: a meta-analysis

Zhewei Shi  1 , Caizhen Qian  2
Affiliations
Meta-Analysis

Copeptin and the prognosis of patients with coronary artery disease: a meta-analysis

Zhewei Shi et al. Ir J Med Sci. 2023 Oct.

Abstract

Objectives: Copeptin, the C-terminal portion of provasopressin, has been regarded as a marker of non-specific stress response and a potentially prognostic biomarker of cardiovascular diseases. This systematic review and meta-analysis was conducted to summarize the predictive role of baseline copeptin for the prognosis of patients with coronary artery disease (CAD).

Methods: Relevant observational studies with longitudinal follow-up were obtained by comprehensive search of PubMed, Embase, and Web of Science databases. A random-effects model was used to pool the results.

Results: Twenty-two studies with 19,821 patients with CAD were enrolled. Results of the meta-analyses revealed that a high copeptin at baseline was associated with a higher mortality risk (risk ratio [RR]: 1.76, 95% confidence interval [CI]: 1.49 to 2.09, p < 0.001; I2 = 70%) and an increased incidence of major adverse cardiovascular events (MACEs, RR: 1.49, 95% CI: 1.34 to 1.65, p < 0.001; I2 = 28%) in patients with CAD. Further results of sensitivity and subgroup analyses showed consistent associations between high copeptin with increased risks of mortality and MACEs in studies of patients with different ages, proportion of men, subtypes of CAD, study design, follow-up durations, and quality scores (p for subgroup effect all < 0.05).

Conclusions: A high plasma level of copeptin is associated with higher risks of mortality and MACEs in patients with CAD. Measuring copeptin may be helpful for risk stratification in patients with CAD.

Keywords: Copeptin; Coronary artery disease; Major adverse cardiovascular events; Meta-analysis; Mortality.

PubMed Disclaimer

Similar articles

See all similar articles

Cited by

References

    1. Libby P, Theroux P (2005) Pathophysiology of coronary artery disease. Circulation 111(25):3481–3488 - PubMed - DOI
    1. Malakar AK, Choudhury D, Halder B et al (2019) A review on coronary artery disease, its risk factors, and therapeutics. J Cell Physiol 234(10):16812–16823 - PubMed - DOI
    1. Arnold SV, Bhatt DL, Barsness GW et al (2020) Clinical management of stable coronary artery disease in patients with type 2 diabetes mellitus: a scientific statement from the American Heart Association. Circulation 141(19):e779–e806 - PubMed - DOI
    1. Jia S, Liu Y, Yuan J (2020) Evidence in guidelines for treatment of coronary artery disease. Adv Exp Med Biol 1177:37–73 - PubMed - DOI
    1. Safiri S, Karamzad N, Singh K et al (2022) Burden of ischemic heart disease and its attributable risk factors in 204 countries and territories, 1990–2019. Eur J Prev Cardiol 29(2):420–431 - PubMed - DOI

LinkOut - more resources